Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

Starting soon · Not applicable

Conditions studied: Cancer

In brief

This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs

Key facts

Study ID

NCT07731425

Run by

London School of Economics and Political Science

People needed

3000

Starts

2026-08-01

Expected to finish

2026-10-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer)
• US adults 18 years of age and older, fluent in English, and residing in the United States.

You may not qualify if…

• Adults who do not have a former cancer diagnosis or who were diagnosed with nonmelanoma skin cancer; adults who complete the survey in under 150 seconds, and who do not meet the other inclusion criteria.

Where it is running

• Harvard Medical School and Harvard Pilgrim Health Care Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.